Fenfluramine hydrochloride is a Small Molecule owned by Zogenix, and is involved in 27 clinical trials, of which 14 were completed, 10 are ongoing, and 3 are planned.

Fenfluramine hydrochloride elicits anti-epileptic properties by elevating the levels of serotonin. Serotonin is a brain chemical which play a important role for well-being and associated behaviors. The drug candidates by selectively inhibiting the serotonin reuptake stimulate the release of serotonin thereby reduce the seizures associated with the disease.

The revenue for Fenfluramine hydrochloride is expected to reach a total of $11.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Fenfluramine hydrochloride NPV Report.

Fenfluramine hydrochloride is currently owned by Zogenix. Nippon Shinyaku and UCB are the other companies associated in development or marketing of Fenfluramine hydrochloride.

Fenfluramine hydrochloride Overview

Fenfluramine hydrochloride (Fintepla) is an amphetamine derivative a sympathomimetic stimulant. It is formulated as solution for oral route of administration. Fintepla is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. Fenfluramine hydrochloride (ZX-008) is under development for the treatment of Dravet syndrome (Severe Myoclonic Epilepsy of Infancy), infantile spasm, Doose syndrome, Lennox Gastaut syndrome as an adjuvant therapy and to treat convulsive seizures in patients with CDKL5 deficiency disorder (a rare developmental epileptic encephalopathy caused by mutations in the CDKL5 gene). It is also under development for the treatment of LGS, convulsive seizures (generalized tonic clonic seizures, tonic seizures, atonic seizures, tonic/atonic seizures, focal seizures with clear observable motor signs.

UCB Overview

UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

The company reported revenues of (Euro) EUR5,777 million for the fiscal year ended December 2021 (FY2021), an increase of 8% over FY2020. In FY2021, the company’s operating margin was 22.2%, compared to an operating margin of 18.2% in FY2020. In FY2021, the company recorded a net margin of 18.3%, compared to a net margin of 13.7% in FY2020.

Quick View – Fenfluramine hydrochloride

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Fenfluramine hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.